AniracetamvsRhodiola Rosea

Aniracetam is a positive allosteric modulator of AMPA receptors, binding to the allosteric site and slowing receptor desensitization, which prolongs excitatory postsynaptic currents and facilitates long-term potentiation. It also modulates group II metabotropic glutamate receptors (mGluR2/mGluR3), which regulate presynaptic glutamate release. Uniquely among racetams, aniracetam increases dopamine and serotonin release in the prefrontal cortex via modulation of monoamine transporter activity and vesicular release, contributing to its anxiolytic and mood-enhancing effects. It reduces GABAergic inhibition in the hippocampus through indirect modulation of GABA-A receptors, facilitating NMDA receptor activation and memory consolidation. The lipophilic phenylacetyl group enables rapid blood-brain barrier penetration.

Rhodiola modulates the hypothalamic-pituitary-adrenal (HPA) axis and reduces cortisol release under stress, possibly through modulation of glucocorticoid receptor sensitivity. Salidroside and rosavins inhibit catechol-O-methyltransferase (COMT) and monoamine oxidase A and B (MAO-A, MAO-B), slowing the breakdown of dopamine, serotonin, and norepinephrine in the brain — increasing catecholamine availability in the prefrontal cortex and limbic system during stress. Rhodiola activates AMP-activated protein kinase (AMPK), a cellular energy sensor that enhances glucose uptake and mitochondrial biogenesis. It has antioxidant effects via activation of Nrf2 and HO-1, protecting neurons from stress-induced oxidative damage. Salidroside may also modulate opioid peptide (beta-endorphin) release and enhance nitric oxide production.